Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 1/20 | 0.40 |
| ▸ | GRM5 | P41594 | 1/20 | 0.32 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14985814 | 0.85 | P2RX7 (0.36) | P2RX7PDK2DPP4 | |
| SCHEMBL23638522 | 0.82 | DPP4 (0.30) | P2RX7DPP4 | |
| SCHEMBL23638651 | 0.80 | — | — | |
| SCHEMBL10166259 | 0.79 | P2RX7 (0.39) | P2RX7GRM5PDK2 | |
| SCHEMBL12211229 | 0.78 | P2RX7 (0.38) | P2RX7GRM5 | |
| SCHEMBL23638713 | 0.77 | — | — | |
| SCHEMBL22330362 | 0.75 | DPP4 (0.44) | P2RX7GRM5DPP4 | |
| SCHEMBL8034374 | 0.74 | POLB (0.48) | P2RX7 | |
| SCHEMBL8025433 | 0.72 | CHRM1 (0.31) | — | |
| SCHEMBL14030258 | 0.72 | POLB (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12024500-B2 | Five-membered ring-substituted pyridazinol compounds and derivatives, preparation methods, herbicidal compositions and applications thereof | QINGDAO KINGAGROOT CHEMICAL COMPOUND CO., LTD. (CN) | 2024-07-02 | — | — | US | disclosed |
| US-20210213006-A1 | METHODS OF TREATING NEURODEGENERATIVE DISEASES | Seal Rock Therapeutics, Inc. | 2021-07-15 | — | — | US | disclosed |
| US-20210087167-A1 | ASK1 INHIBITOR COMPOUNDS AND USES THEREOF | Seal Rock Therapeutics, Inc. | 2021-03-25 | — | — | US | disclosed |
| WO-2020046975-A1 | METHODS OF TREATING NEURODEGENERATIVE DISEASES | Seal Rock Therapeutics, Inc. (US) | 2020-03-05 | — | — | WO | disclosed |
| WO-2019136025-A1 | ASK1 INHIBITOR COMPOUNDS AND USES THEREOF | Seal Rock Therapeutics, Inc. (US) | 2019-07-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12024500-B2 | Five-membered ring-substituted pyridazinol compounds and derivatives, preparation methods, herbicidal compositions and applications thereof | DDT, CYP3A5, CYP4B1 | P2RX7 210/4885GRM5 112/4885PDK2 209/4885 |
| US-20210087167-A1 | ASK1 INHIBITOR COMPOUNDS AND USES THEREOF | ATF1, MAP3K1, ROCK1 | P2RX7 4582/4885GRM5 4690/4885PDK2 1016/4885 |
| US-20210213006-A1 | METHODS OF TREATING NEURODEGENERATIVE DISEASES | SNCA, MAPT, HTT | P2RX7 3991/4885GRM5 2114/4885PDK2 407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.